Low adherence to antipsychotic medication linked to long-term homelessness

NewsGuard 100/100 Score

SFU health sciences researcher Stefanie Rezansoff has published a new study on the treatment of serious mental illnesses among people who are homeless. This is the first study to investigate adherence to antipsychotic medication in this population.

She found only 12 per cent of the 290 individuals studied were adherent to their medications at the level needed to be effective. This is despite having full drug coverage and high access to pharmacies.

"Treatment protocols recommend that patients receive these medications continuously once they're initiated, but this can be difficult to ensure when people are precariously housed," says Rezansoff. "There's a strong link between low adherence and long-term homelessness."

Serious mental illnesses such as schizophrenia are overrepresented among homeless people. When symptoms are not effectively managed, individuals are at a higher risk of hospitalization, arrest, victimization and even suicide.

The research team is currently investigating interventions to improve adherence to antipsychotic medications. Possible interventions include supported housing, prescribing long-acting injections, and initiating regular and frequent contact between patients and primary healthcare providers.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.